Wireless Implantable Mandarin Chinese Speech Neuroprosthesis Evaluation (WISE)
2026年9月8日 更新者:Shanghai StairMed Technology Co., Ltd.
This prospective, single-arm clinical trial is designed to preliminarily evaluate the safety and efficacy of an implantable wireless brain-computer interface (BCI) system (manufactured by Shanghai StairMed Technology Co., Ltd.) in enabling subjects with speech disorders to achieve brain-controlled interaction and communication.
Eligible subjects will undergo surgical implantation of the device and receive brain-control training.
All participants will be followed for an expected period of 12 months.
During the follow-up, adverse events, serious adverse events, and device deficiencies will be recorded, and efficacy data on brain-controlled interaction and communication will be collected.
The goal is to conduct an initial assessment of the safety and effectiveness of the investigational device in achieving brain-controlled effects in the target population.
研究概览
研究类型
介入性
注册 (估计的)
4
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Clinical team Stairmed
- 电话号码:+86 021-80510178
- 邮箱:yumiao@stairmed.com
学习地点
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国
- 招聘中
- Huashan Hospital, Fudan University
-
接触:
- Ying Mao, Ph.D
- 电话号码:+86 021 5288 8045
- 邮箱:maoying@fudan.edu.cn
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Age 18 to 80 years (inclusive), any gender.
- Clinically diagnosed with speech disorders, including locked-in syndrome, severe dysarthria, aphasia with preserved auditory comprehension, or late-stage ALS-related language dysfunction, secondary to stroke, traumatic brain injury, amyotrophic lateral sclerosis (ALS), or other motor neuron diseases.
- The subject, or the subject with the assistance of their legal representative, is willing to follow the investigator's instructions, adhere to all protocol-specified procedures, and complete all required follow-up.
- The subject and their legal representative fully understand the purpose and significance of the trial; the subject voluntarily agrees to participate and signs the informed consent form
Exclusion Criteria:
- Subjects with any previously implanted metallic objects or devices (e.g., pacemakers, defibrillators, neurostimulators, cochlear implants), except for dental metal implants or implants assessed to have no impact on the trial.
- Subjects who have been on long-term anticoagulant or antiplatelet therapy prior to screening, with antiplatelet drugs discontinued for less than 2 weeks before surgery; or subjects with hematological or autoimmune disorders (e.g., aplastic anemia, systemic lupus erythematosus); or subjects with clinically significant coagulation test abnormalities during the screening period.
- Subjects assessed by an anesthesiologist to be unable to tolerate anesthesia and surgery.
- Subjects assessed by the investigator to have nervous system diseases (e.g., cerebrovascular lesions, intracranial infections, neurodegenerative diseases, epilepsy) or a history of craniocerebral trauma, resulting in severe brain function impairment or marked EEG abnormalities.
- Subjects with physiological or pathological conditions that may lead to poor healing of scalp wounds.
- Subjects in the acute infection phase or suffering from other severe infections.
- Subjects with cognitive impairment or psychotic symptoms.
- Subjects with severe dysfunction of vital organs (heart, lung, liver, kidney, etc.), malignant tumors or autoimmune diseases, who are deemed ineligible for this clinical trial by investigators.
- Subjects judged by investigators to have an expected survival time of less than 1 year.
- Subjects with drug abuse or alcohol dependence.
- Pregnant or breastfeeding women, or subjects planning to become pregnant during the trial period.
- Subjects currently participating in clinical trials of drugs or other medical devices.
- Subjects unable to understand or read Chinese.
- Other circumstances under which investigators consider the subject unsuitable to participate in this clinical trial
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:设备可行性
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Implantation of the WRS
|
WRS is a minimally invasive, wireless brain-machine interface system.
Subjects with speech disorders undergo implantation of WRS, receive brain-control training, and are followed up.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Device-Related Adverse Events
大体时间:From implantation to Month 12
|
Adverse events determined by the investigator to be related to the investigational device, recorded throughout the study period.
|
From implantation to Month 12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of All Adverse Events
大体时间:From implantation to Month 12
|
From implantation to Month 12
|
|
|
Incidence of Device Deficiencies
大体时间:From implantation to Month 12
|
From implantation to Month 12
|
|
|
Number of Reliable Recording Channels at Each Evaluation Time Point
大体时间:At 3, 6, 9, and 12 months post-implantation
|
At 3, 6, 9, and 12 months post-implantation
|
|
|
Speech Output Rate in Characters Per Minute (CPM)
大体时间:At 3, 6, 9, and 12 months post-implantation
|
The speech output rate, defined as the number of Chinese characters produced per unit time during task performance, is calculated and documented every 3 months during the follow-up period.
|
At 3, 6, 9, and 12 months post-implantation
|
|
Speech Output Character Error Rate (CER)
大体时间:At 3, 6, 9, and 12 months post-implantation
|
The subject independently outputs the complete sequence of Chinese characters from a standard reference text.
The minimum edit distance (total substitutions, deletions, and insertions) between the decoded sequence and the reference sequence is divided by the total number of Chinese characters in the reference text to obtain the character error rate.
Recorded every 3 months during follow-up.
|
At 3, 6, 9, and 12 months post-implantation
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2026年9月1日
初级完成 (估计的)
2028年8月30日
研究完成 (估计的)
2028年12月30日
研究注册日期
首次提交
2026年6月9日
首先提交符合 QC 标准的
2026年6月9日
首次发布 (实际的)
2026年6月15日
研究记录更新
最后更新发布 (实际的)
2026年9月11日
上次提交的符合 QC 标准的更新
2026年9月8日
最后验证
2026年9月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.